de Jonghe E, Murray C J, Chum H J, Nyangulu D S, Salomao A, Styblo K
Int J Health Plann Manage. 1994 Apr-Jun;9(2):151-81. doi: 10.1002/hpm.4740090204.
The cost-effectiveness of chemotherapy for pulmonary sputum smear-positive tuberculosis was examined in the national tuberculosis control programmes of Malawi, Mozambique and Tanzania. In these three programmes, routine cure rates have exceeded 80 per cent. Average, average incremental and marginal unit costs for standard, short-course and retreatment regimens with and without hospitalization have been measured. The average incremental cost per year of life saved through chemotherapy ranged from US $0.90-3.10. In all conditions, short-course chemotherapy is preferable to standard 12-month chemotherapy. When hospitalization during the intensive phase of chemotherapy increases the cure rate by 10-15 percentage points, it can be relatively cost-effective. Analysing the cost-effectiveness of short-course and standard chemotherapy, where the depth of the margin of benefit is different, illustrates some of the dangers of simplistic use of cost-effectiveness ratios.
在马拉维、莫桑比克和坦桑尼亚的国家结核病控制项目中，对痰涂片阳性肺结核化疗的成本效益进行了研究。在这三个项目中，常规治愈率已超过80%。已测量了有或无住院治疗情况下标准、短程和复治方案的平均、平均增量和边际单位成本。通过化疗每年挽救一条生命的平均增量成本在0.90美元至3.10美元之间。在所有情况下，短程化疗优于标准的12个月化疗。当化疗强化期住院可使治愈率提高10 - 15个百分点时，可能具有相对成本效益。分析短程和标准化疗的成本效益，其中效益边际深度不同，说明了简单使用成本效益比的一些风险。
